EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Legacy of a magic gene— CCR5- ∆ 32 : From discovery to clinical benefit in a generation

Stephen J OBrien iD

Proceedings of the National Academy of Sciences · 19.03.2024 · 121 (12)

DOI: 10.1073/pnas.2321907121 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, online erschienen am 08.03.2024. Verfasst von Stephen J OBrien. Beteiligte Einrichtung: Guy Harvey Oceanographic Center, Halmos College of Arts and Sciences, Nova Southeastern University, Ft Lauderdale, FL 33004. Hauptthemen laut MEDLINE: HIV Infections, Acquired Immunodeficiency Syndrome. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 101 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI-NIH Intramural Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The discovery of the 32-bp deletion allele of the chemokine receptor gene CCR5 showed that homozygous carriers display near-complete resistance to HIV infection, irrespective of exposure. Algorithms of molecular evolutionary theory suggested that the CCR5- ∆ 32 mutation occurred but once in the last millennium and rose by strong selective pressure relatively recently to a ~10% allele frequency in Europeans. Several lines of evidence support the hypothesis that CCR5- ∆ 32 was selected due to its protective influence to resist Yersinia pestis, the agent of the Black Death/bubonic plague of the 14th century. Powerful anti-AIDS entry inhibitors targeting CCR5 were developed as a treatment for HIV patients, particularly those whose systems had developed resistance to powerful anti-retroviral therapies. Homozygous CCR5- ∆ 32/ ∆ 32 stem cell transplant donors were used to produce HIV-cleared AIDS patients in at least five “cures” of HIV infection. CCR5 has also been implicated in regulating infection with Staphylococcus aureus , in recovery from stroke, and in ablation of the fatal graft versus host disease (GVHD) in cancer transplant patients. While homozygous CCR5- ∆ 32/32 carriers block HIV infection, alternatively they display an increased risk for encephalomyelitis and death when infected with the West Nile virus.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV InfectionsAcquired Immunodeficiency SyndromeHumansGene FrequencyReceptors, CCR5MutationHomozygote

Stichwörter der Autor:innen

AIDSCCR5genetic epidemiologynatural histories

Substanzen

Receptors, CCR5CCR5 protein, human

Autor:innen und Institutionen

  • Guy Harvey Oceanographic Center, Halmos College of Arts and Sciences, Nova Southeastern University, Ft Lauderdale, FL 33004.
  • Indiana University School of Public Health, Bloomington, IN 47405.

ORCID-Profile: Stephen J OBrien

Förderung

  • NCI-NIH Intramural Program

Zitieren

APA

OBrien, S. J. (2024). Legacy of a magic gene— CCR5- ∆ 32 : From discovery to clinical benefit in a generation. Proceedings of the National Academy of Sciences, 121(12). https://doi.org/10.1073/pnas.2321907121

Vancouver

OBrien SJ. Legacy of a magic gene— CCR5- ∆ 32 : From discovery to clinical benefit in a generation. Proceedings of the National Academy of Sciences. 2024;121(12). doi:10.1073/pnas.2321907121

BibTeX
@article{OBrien2024,
  author = {OBrien, Stephen J},
  title = {Legacy of a magic gene— CCR5- ∆ 32 : From discovery to clinical benefit in a generation},
  journal = {Proceedings of the National Academy of Sciences},
  year = {2024},
  volume = {121},
  number = {12},
  doi = {10.1073/pnas.2321907121}
}
Kostenlos starten →